| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
29,761 |
26,261 |
$4.50M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
17,134 |
14,504 |
$2.21M |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
1,608 |
782 |
$1.01M |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
11,143 |
8,589 |
$686K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
6,920 |
2,096 |
$577K |
| 71046 |
Radiologic examination, chest; 2 views |
4,352 |
3,684 |
$498K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
1,838 |
1,536 |
$435K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
3,697 |
3,042 |
$329K |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
1,149 |
501 |
$287K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
37,031 |
30,312 |
$163K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
1,790 |
1,427 |
$163K |
| 71045 |
Radiologic examination, chest; single view |
1,107 |
923 |
$162K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
29,315 |
24,610 |
$140K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
335 |
281 |
$123K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,671 |
1,552 |
$118K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
2,053 |
1,105 |
$110K |
| 87631 |
|
1,001 |
864 |
$90K |
| 36415 |
Collection of venous blood by venipuncture |
33,822 |
27,343 |
$86K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
2,282 |
1,618 |
$77K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
2,038 |
1,606 |
$66K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
2,372 |
1,937 |
$62K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
2,356 |
1,925 |
$61K |
| 80076 |
|
9,018 |
7,581 |
$46K |
| 80053 |
Comprehensive metabolic panel |
6,222 |
4,923 |
$42K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
1,199 |
898 |
$33K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
5,689 |
4,640 |
$29K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
166 |
151 |
$27K |
| 84484 |
|
3,495 |
2,767 |
$26K |
| 81025 |
|
4,249 |
3,628 |
$25K |
| 84443 |
Thyroid stimulating hormone (TSH) |
1,854 |
1,625 |
$23K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
419 |
271 |
$19K |
| 81001 |
|
9,901 |
8,411 |
$18K |
| 97597 |
|
149 |
87 |
$18K |
| 45385 |
Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) |
13 |
13 |
$17K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
408 |
353 |
$17K |
| 83690 |
|
4,475 |
3,732 |
$16K |
| 96367 |
|
338 |
151 |
$16K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
279 |
231 |
$14K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
119 |
102 |
$13K |
| 80061 |
Lipid panel |
1,227 |
1,125 |
$12K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
20 |
12 |
$11K |
| 86803 |
|
993 |
752 |
$10K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
253 |
209 |
$10K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
228 |
177 |
$9K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
499 |
401 |
$8K |
| 83605 |
|
1,118 |
886 |
$8K |
| 82728 |
|
831 |
753 |
$7K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
265 |
116 |
$6K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
119 |
73 |
$6K |
| 85027 |
|
1,072 |
950 |
$5K |
| 83550 |
|
824 |
750 |
$5K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
547 |
493 |
$4K |
| 86762 |
|
415 |
315 |
$4K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
283 |
107 |
$4K |
| 70450 |
Computed tomography, head or brain; without contrast material |
41 |
36 |
$4K |
| 83540 |
|
824 |
751 |
$3K |
| 87340 |
|
492 |
379 |
$3K |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
184 |
161 |
$3K |
| 84439 |
|
376 |
344 |
$2K |
| 88142 |
|
251 |
194 |
$2K |
| 83880 |
|
90 |
77 |
$2K |
| 86850 |
|
493 |
388 |
$2K |
| 86592 |
|
603 |
470 |
$2K |
| 81003 |
|
1,306 |
1,106 |
$2K |
| 83655 |
|
120 |
113 |
$1K |
| 83970 |
|
58 |
54 |
$1K |
| 85379 |
|
195 |
158 |
$1K |
| 73630 |
|
28 |
25 |
$1K |
| 82607 |
|
122 |
110 |
$1K |
| 73564 |
|
22 |
13 |
$959.52 |
| 86900 |
|
416 |
323 |
$859.48 |
| 86901 |
|
416 |
323 |
$856.58 |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
31 |
26 |
$701.80 |
| 83735 |
|
160 |
138 |
$694.44 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
886 |
539 |
$635.75 |
| J7050 |
Infusion, normal saline solution, 250 cc |
318 |
235 |
$516.24 |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
39 |
26 |
$468.25 |
| 83615 |
|
105 |
97 |
$367.39 |
| 87660 |
|
30 |
24 |
$365.60 |
| 87480 |
|
30 |
24 |
$345.55 |
| 87510 |
|
30 |
24 |
$345.55 |
| 80069 |
|
45 |
42 |
$223.67 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
14 |
12 |
$198.15 |
| 82565 |
|
68 |
56 |
$179.50 |
| 82746 |
|
17 |
15 |
$171.18 |
| 84460 |
|
67 |
56 |
$167.45 |
| 84450 |
|
67 |
56 |
$163.70 |
| J2469 |
Injection, palonosetron hcl, 25 mcg |
25 |
12 |
$137.20 |
| 82570 |
|
40 |
40 |
$130.99 |
| 83883 |
|
28 |
13 |
$122.40 |
| 84156 |
|
40 |
40 |
$91.07 |
| 85046 |
|
15 |
13 |
$53.69 |
| 84165 |
|
19 |
14 |
$52.70 |
| 84155 |
|
19 |
14 |
$22.02 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,055 |
773 |
$0.00 |
| 87205 |
|
18 |
12 |
$0.00 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
182 |
120 |
$0.00 |
| J2175 |
Injection, meperidine hydrochloride, per 100 mg |
165 |
120 |
$0.00 |
| G0475 |
Hiv antigen/antibody, combination assay, screening |
54 |
42 |
$0.00 |
| 87077 |
|
17 |
12 |
$0.00 |
| 87070 |
|
18 |
12 |
$0.00 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
289 |
209 |
$0.00 |